Skip to main content
Premium Trial:

Request an Annual Quote

Q Bio Raises $40M in Series B Financing Round

NEW YORK — Q Bio said on Thursday that it has raised $40 million in Series B funding that it will use to further develop its preventative health technology.

The round was led by venture capital firm Andreessen Horowitz and included Khosla Ventures, Founders Fund, Beast Ventures, Thirty5 Ventures, Sea Lane Ventures, and SciFi VC. In conjunction with the financing, Andreessen Horowitz's Vijay Pande and Khosla Venture's Vinod Khosla will join Q Bio's board.

Including the Series B funding, Q Bio said it has raised $58 million to date.

Founded in 2015, Q Bio is developing a platform that is designed to provide an overview of an individual's health based on their vital signs, a whole-body MRI, blood and urine analyses, and sequenced genetic data. Readouts are available within 75 minutes and can be accessed online by a patient's healthcare provider.

Q Bio said that it opened its first facility in Redwood City, California in late 2019 and that additional locations are planned for later this year.

"By measuring everything from blood to imaging and more in a longitudinal way, patients can have personalized baselines and physicians the data and power to understand, interpret, and utilize this data to personalize care," Pande said in a statement.